Testosterone Replacement Therapy Duration and Monitoring

Initial Evaluation and Diagnosis

Hypogonadism should be confirmed with at least two separate morning testosterone measurements showing low levels, and distinguish between primary and secondary hypogonadism by measuring luteinizing hormone and follicle-stimulating hormone, according to the Endocrine Society 1
Rule out other causes of hypogonadism through appropriate workup, which may include prolactin levels, iron saturation, pituitary function testing, and possibly MRI of the sella turcica, as recommended by the Endocrine Society 1

No specific endpoint for discontinuation exists in current guidelines for men with confirmed hypogonadism, and treatment should be continued as long as the patient experiences clinical benefits and no significant adverse effects develop, according to the American College of Physicians 3
The American College of Physicians suggests continuing treatment as long as clinical benefits persist and no significant adverse effects develop, with regular monitoring every 6-12 months to assess continued efficacy and safety 3

Initial testosterone level testing should be performed 2-3 months after treatment initiation or dose change, and once stable levels are achieved, monitoring every 6-12 months is typically sufficient, as recommended by the Endocrine Society 1

The American College of Physicians suggests considering intramuscular rather than transdermal formulations due to lower cost with similar effectiveness and safety profile 4
Transdermal preparations provide more stable day-to-day testosterone levels but are more expensive, while intramuscular injections are more economical but may cause fluctuating levels, according to the Endocrine Society 1

Symptoms should be reevaluated within 12 months of starting treatment and periodically thereafter, and if no improvement in sexual function or other targeted symptoms occurs, discontinuation should be considered, as recommended by the American College of Physicians 4
Treatment should be individualized based on symptom response, not just testosterone levels, according to the American College of Physicians 3

Evidence from observational studies shows no increased risk for mortality, cardiovascular events, prostate cancer, or venous thromboembolism, but long-term safety data beyond 10 years is limited, according to the American College of Physicians 3
Monitor for potential adverse effects including erythrocytosis, which occurs in 3-18% with transdermal administration and up to 44% with injections, as reported in the New England Journal of Medicine 6

Not performing regular monitoring of both efficacy and safety parameters, as recommended by the Endocrine Society 1
Continuing treatment despite lack of symptom improvement, according to the American College of Physicians 5
Ignoring cardiovascular risk factors, as most studies excluded men with recent cardiovascular disease, as noted by the American College of Physicians 3